Deutsche Bank maintains ‘buy' on Creo Medical after strong FY25 growth

Deutsche Bank reiterated its 'buy' on Creo Medical after a trading update confirming 50% revenue growth in FY25, maintaining a 40p price target while the shares traded around 11.6–11.75p. Analyst Kane Slutzkin highlighted stronger product adoption, reliable revenue performance and good cost control, left FY26 estimates unchanged but noted potential upside from the second-half run rate ahead of preliminary results in April; the stock still trades at a significant discount to Deutsche’s DCF valuation.

Analysis

Market structure: Creo (AIM:CREO) is the clear near-term beneficiary—50% FY25 revenue growth implies accelerating adoption and a rising install base that should lift recurring consumables and service revenue over 12–24 months. Suppliers of disposables and hospital buyers gain bargaining clarity; incumbents without differentiated electrosurgical platforms are the losers as share shifts to newer entrants. The 11.7p stock vs Deutsche’s 40p PT implies market pricing of execution risk rather than demand; if H2 run‑rate sustains, pricing power for consumables could materially improve gross margins by 300–500bps over 12–18 months.

Risk assessment: Key tail risks are regulatory setbacks (MHRA/US FDA delays), single‑product concentration, and a shorter cash runway forcing dilutive funding; each could erase >40–60% of current market value. Near term (days–weeks) the stock is sensitive to the April prelims and any install‑base metrics; medium term (3–12 months) execution on commercial roll‑out and margin expansion matter; long term (12–36 months) realization of DCF upside to 40p depends on recurring revenue scale. Hidden dependency: revenue is likely concentrated among a small hospital cohort—loss of a few customers or reversal in purchasing cycles is a non‑linear downside.

Trade implications: Tactical long exposure is warranted but sized and hedged—establish 2–3% portfolio long at current levels, target 40p in 12–18 months, stop at 7.5p to limit tail losses. Use asymmetric option structures (12‑month call spreads) to cap cash outlay: e.g., buy 10p/40p call spread or 15p/40p if liquidity dictates, sizing options to 0.5–1% portfolio. Rotate capital away from undifferentiated UK small‑cap healthcare names into high‑growth medtechs with clear recurring revenue; trim position by 50% at 25p and re‑assess.

Contrarian angles: The market’s muted 1% move suggests upside underreaction driven by liquidity and execution risk rather than fundamentals—this creates mispricing if adoption continues. Consensus may be underestimating concentration and funding risk; if April prelims show H2 run‑rate beating Deutsche’s base case by >20%, the re‑rating could be rapid (100–200%+), but conversely a downgrade or cash‑flow miss could trigger >50% drawdown. Historical parallel: small medtech re‑ratings hinge on reproducible consumable attach rates and reimbursement stability—verify both before adding materially.

Key Decisions for Investors

• Establish a 2–3% portfolio long in Creo Medical (AIM:CREO) at current levels (~11.7p), target 40p within 12–18 months (Deutsche DB PT), and implement a hard stop-loss at 7.5p to cap downside (~‑36%).
• Allocate 0.5–1% to options: buy a 12‑month call spread (prefer 10p/40p or 15p/40p depending on liquidity) to maintain upside exposure with defined cost; if single‑leg only, buy 12‑month 15p calls sizing max loss to 1% portfolio.
• Scale into a full 4–5% position only if April preliminary results confirm H2 revenue run‑rate > company guidance (add on confirmation of >30% YoY revenue growth or install‑base growth >20% QoQ); otherwise hold at 2–3%.
• Do not initiate or reduce exposure if April prelims show cash runway <12 months, material guidance cut, or install‑base growth <10% QoQ—those are actionable red flags that imply likely dilution and >50% downside risk.